Visual Outcomes Following Infectious Endophthalmitis from Intravitreal Injections of Biologic Drugs: An Intelligent Research in Sight Registry Retrospective Analysis.

Ophthalmol Ther · 2026 · PMC13249980 · PMID 42033607

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Our study showed a highly significant difference in post-IVT-injection infectious endophthalmitis rates of aflibercept 2 mg over ranibizumab, and this may be due to the very large sample size available through the IRIS ® Registry to be able to show a statistical difference.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.